Synaptys Neuroscience
SYNAPTYS neuroscience is a French biotech company developing a multimodal therapeutic candidate for Alzheimer’s disease. The organisation focuses on preclinical discovery and development of combination small-molecule strategies that modulate glutamatergic signaling and calcium homeostasis, using bibliographic synthesis, in vivo models and AI-derived synergy optimization. The company collaborates with public research institutes and private partners, manages intellectual property, and is progressing toward clinical development.
Industries
Nr. of Employees
small (1-50)
Synaptys Neuroscience
Products
Multimodal combination therapeutic candidate (NMDA receptor antagonist + vitamin D) — preclinical
A preclinical therapeutic candidate combining NMDA receptor antagonism with vitamin D–based calcium modulation to provide synergistic neuroprotection and stabilise cognitive functions in models of Alzheimer’s disease.
Multimodal combination therapeutic candidate (NMDA receptor antagonist + vitamin D) — preclinical
A preclinical therapeutic candidate combining NMDA receptor antagonism with vitamin D–based calcium modulation to provide synergistic neuroprotection and stabilise cognitive functions in models of Alzheimer’s disease.
Services
Collaborative research projects with academic and private laboratories to advance preclinical evaluation of therapeutic candidates.
Coordination with external regulatory affairs consultants and patent firms to support development and protection of therapeutic assets.
Collaborative research projects with academic and private laboratories to advance preclinical evaluation of therapeutic candidates.
Coordination with external regulatory affairs consultants and patent firms to support development and protection of therapeutic assets.
Expertise Areas
- Preclinical neurodegenerative disease research
- Combination therapeutic design
- Neuroscience and neuroprotection assays
- AI-assisted drug synergy optimization
Key Technologies
- AI-driven synergy optimization
- NMDA receptor antagonism
- Vitamin D–mediated calcium signaling modulation
- In vivo neurodegeneration (animal) models
News & Updates
Initial preclinical studies demonstrate synergistic neuroprotective effects, improved cognitive measures and reduction of disease markers in animal models.
Bibliographic research and published studies (over 20) cited by the organisation that validate the scientific hypotheses behind the therapeutic strategy.
Organisation reports more than 13 years of research underpinning current therapeutic development.
Development carried out by an international team of researchers across France, the United States, Canada and Spain, supported by multiple scientific partners.
Initial preclinical studies demonstrate synergistic neuroprotective effects, improved cognitive measures and reduction of disease markers in animal models.
Bibliographic research and published studies (over 20) cited by the organisation that validate the scientific hypotheses behind the therapeutic strategy.
Organisation reports more than 13 years of research underpinning current therapeutic development.
Development carried out by an international team of researchers across France, the United States, Canada and Spain, supported by multiple scientific partners.